Lv22
198 积分 2025-08-03 加入
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
1小时前
待确认
Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series
14天前
已完结
Sustained Minimal Manifestations With Extended Interval Dosing of Efgartigimod in Seronegative Myasthenia Gravis: Case Report
14天前
已完结
Efgartigimod versus standard of care in new-Onset AChR subtype generalized myasthenia gravis: A prospective cohort study
1个月前
已完结
FcRn inhibition with efgartigimod ameliorates muscle weakness and modulates dendritic cell subsets in an experimental autoimmune myasthenia gravis mouse model
1个月前
已完结
Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy
1个月前
已完结
Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis
1个月前
已完结
Myasthenic crisis
1个月前
已完结
Poor responses and adverse outcomes of myasthenia gravis after thymectomy: Predicting factors and immunological implications
1个月前
已完结
Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders
1个月前
已完结
皖公网安备34019202002308
